US Stock MarketDetailed Quotes
RCUS Arcus Biosciences
- 15.700
- +0.200+1.29%
Close May 3 16:00 ET
- 15.960
- +0.260+1.66%
Post 16:53 ET
1.43BMarket Cap-3783P/E (TTM)
16.360High15.490Low538.28KVolume15.970Open15.500Pre Close8.46MTurnover0.99%Turnover RatioLossP/E (Static)90.95MShares25.47052wk High3.09P/B855.26MFloat Cap12.95052wk Low--Dividend TTM54.48MShs Float49.100Historical High--Div YieldTTM5.61%Amplitude6.300Historical Low15.708Avg Price1Lot Size
Arcus Biosciences Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | (Q1)Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -169.86%-306M | -25.71%-88M | 22.22%-63M | 12.31%-57M | -114.98%-98M | 271.09%438M | -13.03%-70M | -50.68%-81M | 12.16%-65M | 1,086.19%654M |
| Net income from continuing operations | -14.98%-307M | -20.90%-81M | -9.23%-71M | -11.94%-75M | -17.65%-80M | -603.77%-267M | -123.97%-67M | 16.64%-65M | 11.81%-67M | 6.33%-68M |
| Depreciation and amortization | 33.33%8M | 200.00%3M | -50.00%1M | 0.00%2M | 100.00%2M | 50.00%6M | -29.43%1M | 107.68%2M | 143.90%2M | 25.00%1M |
| Other non cash items | -9.09%10M | 0.00%2M | 200.00%3M | -33.33%2M | -40.00%3M | 266.67%11M | 53.96%2M | 71.23%1M | 418.13%3M | 829.37%5M |
| Change In working capital | -111.40%-71M | -14.29%-24M | 74.29%-9M | --0 | -105.45%-38M | 265.69%623M | 94.18%-21M | -622.86%-35M | -31.42%-18M | 8,469.36%697M |
| -Change in receivables | -97.87%15M | --0 | 57.14%11M | 66.67%-2M | -99.16%6M | 4,241.18%704M | 30.14%-12M | 894.32%7M | -263.93%-6M | 17,180.75%715M |
| -Change in payables and accrued expense | -112.50%-1M | -75.00%2M | 150.00%6M | -575.00%-19M | 25.00%10M | 260.00%8M | 133.58%8M | -201.88%-12M | 218.06%4M | -23.31%8M |
| -Change in other current assets | -800.00%-14M | -133.33%-2M | -57.14%-11M | -30.00%7M | -14.29%-8M | 166.67%2M | 260.00%6M | -2,608.96%-7M | 2,350.98%10M | -11,211.11%-7M |
| -Change in other current liabilities | -114.29%-3M | -163.64%-7M | 70.00%17M | 700.00%8M | -2,000.00%-21M | 23.53%21M | -40.24%11M | 2,587.56%10M | 351.26%1M | -64.74%-1M |
| -Change in other working capital | 39.29%-68M | 50.00%-17M | 3.03%-32M | 122.22%6M | -38.89%-25M | 69.57%-112M | 89.99%-34M | -248.80%-33M | -185.38%-27M | -90.25%-18M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -169.86%-306M | -25.71%-88M | 22.22%-63M | 12.31%-57M | -114.98%-98M | 271.09%438M | -13.03%-70M | -50.68%-81M | 12.16%-65M | 1,086.19%654M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 146.97%194M | -40.43%28M | -52.17%11M | 112.09%26M | 148.13%129M | -10,225.00%-413M | 150.24%47M | 125.96%23M | -7,259.51%-215M | -526.57%-268M |
| Net PPE purchase and sale | -300.00%-24M | ---6M | -400.00%-10M | -400.00%-5M | 0.00%-3M | 76.92%-6M | --0 | 74.55%-2M | 83.53%-1M | 17.61%-3M |
| Net intangibles purchase and sale | --0 | --0 | --0 | ---- | ---- | ---3M | --0 | --3M | ---- | ---- |
| Net investment purchase and sale | 153.96%218M | -27.66%34M | -4.55%21M | 114.90%31M | 149.81%132M | -1,936.36%-404M | 72.73%47M | 127.24%22M | -2,391.76%-208M | -498.69%-265M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 146.97%194M | -40.43%28M | -52.17%11M | 112.09%26M | 148.13%129M | -10,225.00%-413M | 150.24%47M | 125.96%23M | -7,259.51%-215M | -526.57%-268M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 0.00%33M | -72.73%3M | 100.00%6M | 475.00%23M | -93.33%1M | -86.08%33M | -2.92%11M | 127.62%3M | 79.29%4M | -93.25%15M |
| Net common stock issuance | 43.48%33M | -50.00%3M | -41.18%10M | 290.00%19M | -90.00%1M | -90.09%23M | -49.03%6M | --17M | -166,566.67%-10M | -95.46%10M |
| Net other financing activities | ---- | ---- | ---- | ---- | ---- | 100.00%10M | --5M | --0 | --0 | --5M |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 0.00%33M | -72.73%3M | 100.00%6M | 475.00%23M | -93.33%1M | -86.08%33M | -2.92%11M | 127.62%3M | 79.29%4M | -93.25%15M |
| Net cash flow | ||||||||||
| Beginning cash position | 38.41%209M | -15.38%187M | -15.58%233M | -56.34%241M | 38.41%209M | -13.22%151M | 21.14%221M | -14.68%276M | 40.73%552M | -13.03%151M |
| Current changes in cash | -236.21%-79M | -375.00%-57M | 16.36%-46M | 97.10%-8M | -92.02%32M | 352.17%58M | 62.29%-12M | 61.01%-55M | -301.39%-276M | 83.41%401M |
| End cash Position | -37.80%130M | -37.80%130M | -15.38%187M | -15.58%233M | -56.34%241M | 38.41%209M | 38.41%209M | 21.14%221M | -14.68%276M | 40.73%552M |
| Free cash flow | -177.46%-330M | -34.29%-94M | 12.05%-73M | 13.89%-62M | -115.51%-101M | 251.06%426M | 0.51%-70M | -34.71%-83M | 10.08%-72M | 1,030.57%651M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg